阿加曲班治疗进展性脑梗死的临床观察

发布时间：2018-05-14 01:07

本文选题：阿加曲班 + 红花注射液　；参考：《医学理论与实践》2013年17期

【摘要】：目的:评价阿加曲班治疗急性进展性脑梗死的临床疗效,探讨进展性脑梗死的有效治疗方法。方法:将60例急性进展性脑梗死患者随机分为两组,各30例。治疗组给予阿加曲班加红花注射液,对照组给予红花注射液加奥扎格雷。治疗期间两组根据基础疾病,酌情给予降压、调控血糖、脱水、脑保护等治疗。两组治疗前及14d后进行NIHSS评分(主要指标)及改良RANKIN评分。记录治疗过程中出现的不良事件。结果:(1)治疗组14d后NIHSS评分及改良RANKIN评分均低于治疗前差异有统计学意义(P0.01),14d后两组比较差异也有统计学意义(P0.05);(2)治疗组总有效率为93.3%,对照组总有效率为76.7%,两组间比较差异无统计学意义(P0.05)。结果显示两种药物治疗急性进展性脑梗死患者均有较好疗效;阿加曲班组疗效优于对照组。结论:进展性脑梗死应用阿加曲班治疗安全有效,值得临床推广。
[Abstract]:Objective: to evaluate the clinical efficacy of Agatripine in the treatment of acute progressive cerebral infarction (ACI). Methods: 60 patients with acute progressive cerebral infarction were randomly divided into two groups, 30 cases in each group. The treatment group was treated with agatoban plus safflower injection, and the control group with safflower injection Gaoh Zagre. During the treatment, the two groups were treated with hypotension, blood glucose, dehydration, brain protection and so on according to the underlying diseases. NIHSS score (main index) and modified RANKIN score were performed before and 14 days after treatment in both groups. Record adverse events during treatment. Results the NIHSS score and modified RANKIN score in the treatment group were significantly lower than those in the control group after 14 days. There was a significant difference between the two groups after 14 days. The total effective rate of the treatment group was 93.3g, and the total effective rate of the control group was 76.70.The comparison between the two groups showed that the total effective rate of the treatment group was 93.3% and that of the control group was 76.70.The total effective rate of the treatment group was significantly lower than that of the control group. The difference was not statistically significant (P 0.05). The results showed that both drugs had better curative effect on patients with acute progressive cerebral infarction, and the effect of agatropan group was better than that of control group. Conclusion: the treatment of progressive cerebral infarction with Agatripine is safe and effective and worthy of clinical promotion.
【作者单位】：天津滨海新区塘沽中医医院脑内科;
【分类号】：R743.3

【相似文献】